Welcome to our dedicated page for Alaunos Therapeutics SEC filings (Ticker: TCRT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to follow Alaunos Therapeutics’ next breakthrough is tough when its SEC disclosures run hundreds of pages of scientific jargon and accounting rules. Whether you’re watching cash runway for TCR-T trials or scanning for FDA milestone updates, the detail is buried deep in 10-K footnotes and sudden 8-K releases.
Stock Titan surfaces the answers in seconds. Our AI-powered summaries turn Alaunos Therapeutics SEC filings explained simply into reality—highlighting pipeline progress, licensing agreements and material risks. Need the latest Alaunos Therapeutics quarterly earnings report 10-Q filing? It’s here with plain-English context and side-by-side metrics. Curious about Alaunos Therapeutics insider trading Form 4 transactions? Real-time alerts track every executive move, so you can spot buying or selling before the market reacts.
Explore every disclosure type in one place:
- Alaunos Therapeutics annual report 10-K simplified – understand R&D spend, patent portfolios and future funding needs.
- Instant analysis of Alaunos Therapeutics 8-K material events explained – from clinical data releases to financing deals.
- Alaunos Therapeutics proxy statement executive compensation – see how leadership is incentivized to advance the TCR-T platform.
- Alaunos Therapeutics earnings report filing analysis – dive into quarter-over-quarter trial costs and milestones.
- Alaunos Therapeutics Form 4 insider transactions real-time – monitor executive stock transactions without scrolling through EDGAR.
Stop sifting through dense biotech language. By understanding Alaunos Therapeutics SEC documents with AI, you’ll quickly gauge clinical momentum, funding strength and insider confidence—all the data you need to make informed decisions.
Director Jaime Vieser of Alaunos Therapeutics (TCRT) reported the acquisition of derivative securities in a Form 4 filing. On June 24, 2025, Vieser purchased 250 shares of Series A-2 Convertible Preferred Stock at $4.49 per share.
Key transaction details:
- The preferred stock is convertible to 55,679.29 shares of common stock
- The securities are held in direct ownership
- The preferred stock is perpetual with no expiration date
- Transaction code 'P' indicates an open market purchase
This insider purchase by a director could signal confidence in the company's future prospects. The convertible preferred stock provides potential upside exposure to common stock while offering preferred stockholder benefits.
Insider Trading Activity Report for Alaunos Therapeutics (TCRT) reveals significant transactions by Director Robert W. Postma. On June 24, 2025, Postma acquired 600 shares of Series A-2 Convertible Preferred Stock at $4.49 per share through WaterMill Asset Management Corp, convertible to 133,630.29 common shares.
Key holdings and transactions include:
- Direct ownership of 29,083 common shares, including recent acquisition of 20,804 shares at $2.92
- Indirect ownership through WaterMill Asset Management Corp of 33,333 common shares
- 500 Series A-1 Preferred Stock (convertible to 181,159 common shares) at $2.76
- Employee Stock Option for 3,737 shares at $10.30, vesting monthly through 2025
Notable ownership restrictions include a 4.99% beneficial ownership limit on converted preferred shares. The filing indicates continued insider investment in the company with diversified security types.
Alaunos Therapeutics (Nasdaq:TCRT) filed an 8-K disclosing a registered direct offering that closed on June 24 2025. The company sold 338,725 common shares at $3.36 and 271,674 pre-funded warrants at $3.359, generating gross proceeds of roughly $2.1 million before fees. Proceeds are earmarked for general corporate purposes, including capital expenditures and working capital. The Securities Purchase Agreement (Ex. 10.1) contains customary covenants; a legal opinion (Ex. 5.1) and a press release (Ex. 99.1) are also included. No other material operational changes were reported.
Alaunos Therapeutics (Nasdaq:TCRT) filed an 8-K reporting a private placement of 850 shares of Series A-2 Convertible Preferred Stock at $1,000 each, raising $850,000.
- Preferred shares carry a 10% annual dividend, payable in additional Series A-2 stock.
- Convertible into common at a fixed $4.49 price, with standard anti-dilution adjustments.
- Holders vote with common stock on an as-converted 1:1 basis.
- 1,000 shares authorized via a new Certificate of Designation; issuance closed on June 24 2025.
- Securities were sold under Rule 506(b); they are unregistered and subject to resale restrictions.
Items 1.01, 3.02, 3.03 and 5.03 disclose the agreement, equity issuance and charter amendment, all of which modify existing shareholder rights.
FAQ
What is the current stock price of Alaunos Therapeutics (TCRT)?
What is the market cap of Alaunos Therapeutics (TCRT)?
What does Alaunos Therapeutics, Inc. specialize in?
What is adoptive TCR-T cell therapy?
What are Neoantigens?
What recent advancements has Alaunos made?
Who manages investor relations for Alaunos Therapeutics?
How does Alaunos ensure effective communication with stakeholders?
When was Alaunos' latest presentation on TCR engineered therapy?
Who presented the latest research from Alaunos?
What is Alaunos' approach to cancer treatment?
How does Alaunos' technology benefit cancer patients?
